BERKELEY, Calif., Nov. 4 /PRNewswire-FirstCall/ -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced that the Company will host a conference call and webcast on Monday, November 10 at 4:30 p.m. Eastern time to discuss third quarter 2008 financial results and provide a general business update.
The call and webcast will follow the release of third quarter 2008 financial results earlier that morning. The webcast can be accessed via XOMA's website at http://www.investorcalendar.com/IC/CEPage.asp?ID=136306 and will be available for replay until close of business on February 3, 2009. Telephone numbers for the live audiocast are 877-407-9205 (U.S. and Canada) and 201-689-8054 (International). Conference ID #: 300591. A telephonic replay will be available beginning approximately two hours after the conclusion of the call until close of business on February 3, 3008. Telephone numbers for the replay are 877-660-6853 (U.S./Canada) and 201-612-7415 (International). Two access numbers are required for the replay: account number 286 and conference ID # 300591.
XOMA discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and cancerous diseases and is engaged in more than 13 active development projects. The Company's expanding pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 629, a synthetic antimicrobial peptide compound derived from bactericidal/permeability-increasing protein.
XOMA's proprietary development pipeline is primarily funded by multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA's technologies and experienced team have contributed to the success of marketed antibody products, including RAPTIVA(r) (efalizumab) for chronic moderate to severe plaque psoriasis, LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for Crohn's disease.
The Company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression technologies. Bacterial cell expression is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses.
In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of 330 employees at its Berkeley location. For more information, please visit http://www.xoma.com.
Certain statements contained herein relating to product development and
shareholder value, or that otherwise relate to future periods, are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on assumptions that may not prove
accurate. Actual results could differ materially from those anticipated due
to certain risks inherent in the biotechnology industry and for companies
engaged in the development of new products in a regulated market. These
risks, including those related to the results of discovery research and
preclinical testing; the timing or results of pending and future clinical
trials (including the design and progress of clinical trials; safety and
efficacy of the products being tested; action, inaction or delay by the
FDA, European or other regulators or their advisory bodies; and analysis or
interpretation by, or submission to, these entities or others of scientific
data); uncertainties regarding the status of biotechnology patents;
uncertainties as to the cost of protecting intellectual property; changes
in the status of the existing collaborative and licensing relationships;
the ability of collaborators, licensees and other third parties to meet
their obligations; market demand for products; scale up and marketing
capabilities; competition; international operations; share price
volatility; XOMA's financing needs and opportunities; and risks associated
with XOMA's status as a Bermuda company, are described in more detail in
XOMA's most recent annual report on Form 10-K and in other SEC filings.
Consider such risks carefully in considering XOMA's prospects.
Media & Investors Contact:
Porter Novelli Life Sciences for XOMA
|SOURCE XOMA Ltd.|
Copyright©2008 PR Newswire.
All rights reserved